Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 184

1.

The insect pathogenic bacterium Xenorhabdus innexi has attenuated virulence in multiple insect model hosts yet encodes a potent mosquitocidal toxin.

Kim IH, Aryal SK, Aghai DT, Casanova-Torres ÁM, Hillman K, Kozuch MP, Mans EJ, Mauer TJ, Ogier JC, Ensign JC, Gaudriault S, Goodman WG, Goodrich-Blair H, Dillman AR.

BMC Genomics. 2017 Dec 1;18(1):927. doi: 10.1186/s12864-017-4311-4.

2.

Etelcalcetide, A Novel Calcimimetic, Prevents Vascular Calcification in A Rat Model of Renal Insufficiency with Secondary Hyperparathyroidism.

Yu L, Tomlinson JE, Alexander ST, Hensley K, Han CY, Dwyer D, Stolina M, Dean C Jr, Goodman WG, Richards WG, Li X.

Calcif Tissue Int. 2017 Dec;101(6):641-653. doi: 10.1007/s00223-017-0319-7. Epub 2017 Oct 16.

3.

A mosquito hemolymph odorant-binding protein family member specifically binds juvenile hormone.

Kim IH, Pham V, Jablonka W, Goodman WG, Ribeiro JMC, Andersen JF.

J Biol Chem. 2017 Sep 15;292(37):15329-15339. doi: 10.1074/jbc.M117.802009. Epub 2017 Jul 27.

4.

Specificity and putative mode of action of a mosquito larvicidal toxin from the bacterium Xenorhabdus innexi.

Kim IH, Ensign J, Kim DY, Jung HY, Kim NR, Choi BH, Park SM, Lan Q, Goodman WG.

J Invertebr Pathol. 2017 Oct;149:21-28. doi: 10.1016/j.jip.2017.07.002. Epub 2017 Jul 13.

PMID:
28712711
5.

Magnetic Resonance Imaging of Alimentary Tract Development in Manduca sexta.

Rowland IJ, Goodman WG.

PLoS One. 2016 Jun 9;11(6):e0157124. doi: 10.1371/journal.pone.0157124. eCollection 2016.

6.

Cinacalcet, dialysate calcium concentration, and cardiovascular events in the EVOLVE trial.

Pun PH, Abdalla S, Block GA, Chertow GM, Correa-Rotter R, Dehmel B, Drüeke TB, Floege J, Goodman WG, Herzog CA, London GM, Mahaffey KW, Moe SM, Parfrey PS, Wheeler DC, Middleton JP.

Hemodial Int. 2016 Jul;20(3):421-31. doi: 10.1111/hdi.12382. Epub 2015 Nov 13.

7.

Calcimimetic and Calcilytic Drugs: Feats, Flops, and Futures.

Nemeth EF, Goodman WG.

Calcif Tissue Int. 2016 Apr;98(4):341-58. doi: 10.1007/s00223-015-0052-z. Epub 2015 Aug 30. Review.

PMID:
26319799
8.

Cardiovascular and Renal Outcomes Trials-Is There a Difference?

Raggi P, Boer R, Goodman WG, Kalantar-Zadeh K, Chertow GM, Belozeroff V.

Am J Cardiol. 2015 Sep 15;116(6):982-8. doi: 10.1016/j.amjcard.2015.06.024. Epub 2015 Jun 26. Review.

9.

Cinacalcet, Fibroblast Growth Factor-23, and Cardiovascular Disease in Hemodialysis: The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial.

Moe SM, Chertow GM, Parfrey PS, Kubo Y, Block GA, Correa-Rotter R, Drüeke TB, Herzog CA, London GM, Mahaffey KW, Wheeler DC, Stolina M, Dehmel B, Goodman WG, Floege J; Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial Investigators*.

Circulation. 2015 Jul 7;132(1):27-39. doi: 10.1161/CIRCULATIONAHA.114.013876. Epub 2015 Jun 9.

PMID:
26059012
10.

The effects of cinacalcet on blood pressure, mortality and cardiovascular endpoints in the EVOLVE trial.

Chang TI, Abdalla S, London GM, Block GA, Correa-Rotter R, Drüeke TB, Floege J, Herzog CA, Mahaffey KW, Moe SM, Parfrey PS, Wheeler DC, Dehmel B, Goodman WG, Chertow GM.

J Hum Hypertens. 2016 Mar;30(3):204-9. doi: 10.1038/jhh.2015.56. Epub 2015 Jun 4.

PMID:
26040438
11.

The Use of Calcimimetics for the Treatment of Secondary Hyperparathyroidism: A 10 Year Evidence Review.

Rodríguez M, Goodman WG, Liakopoulos V, Messa P, Wiecek A, Cunningham J.

Semin Dial. 2015 Sep-Oct;28(5):497-507. doi: 10.1111/sdi.12357. Epub 2015 Mar 8. Review.

PMID:
25752650
12.

The Effects of Cinacalcet in Older and Younger Patients on Hemodialysis: The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial.

Parfrey PS, Drüeke TB, Block GA, Correa-Rotter R, Floege J, Herzog CA, London GM, Mahaffey KW, Moe SM, Wheeler DC, Kubo Y, Dehmel B, Goodman WG, Chertow GM; Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial Investigators.

Clin J Am Soc Nephrol. 2015 May 7;10(5):791-9. doi: 10.2215/CJN.07730814. Epub 2015 Feb 20.

13.

Effects of Cinacalcet on Fracture Events in Patients Receiving Hemodialysis: The EVOLVE Trial.

Moe SM, Abdalla S, Chertow GM, Parfrey PS, Block GA, Correa-Rotter R, Floege J, Herzog CA, London GM, Mahaffey KW, Wheeler DC, Dehmel B, Goodman WG, Drüeke TB; Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial Investigators.

J Am Soc Nephrol. 2015 Jun;26(6):1466-75. doi: 10.1681/ASN.2014040414. Epub 2014 Dec 11.

14.

Effects of cinacalcet on atherosclerotic and nonatherosclerotic cardiovascular events in patients receiving hemodialysis: the EValuation Of Cinacalcet HCl Therapy to Lower CardioVascular Events (EVOLVE) trial.

Wheeler DC, London GM, Parfrey PS, Block GA, Correa-Rotter R, Dehmel B, Drüeke TB, Floege J, Kubo Y, Mahaffey KW, Goodman WG, Moe SM, Trotman ML, Abdalla S, Chertow GM, Herzog CA; EValuation Of Cinacalcet HCl Therapy to Lower CardioVascular Events (EVOLVE) Trial Investigators.

J Am Heart Assoc. 2014 Nov 17;3(6):e001363. doi: 10.1161/JAHA.114.001363. Erratum in: J Am Heart Assoc. 2015 Jan;4(1):e000570.

15.

Bone histomorphometry before and after long-term treatment with cinacalcet in dialysis patients with secondary hyperparathyroidism.

Behets GJ, Spasovski G, Sterling LR, Goodman WG, Spiegel DM, De Broe ME, D'Haese PC.

Kidney Int. 2015 Apr;87(4):846-56. doi: 10.1038/ki.2014.349. Epub 2014 Oct 22.

16.

The clinical course of treated hyperparathyroidism among patients receiving hemodialysis and the effect of cinacalcet: the EVOLVE trial.

Parfrey PS, Chertow GM, Block GA, Correa-Rotter R, Drüeke TB, Floege J, Herzog CA, London GM, Mahaffey KW, Moe SM, Wheeler DC, Dehmel B, Trotman ML, Modafferi DM, Goodman WG.

J Clin Endocrinol Metab. 2013 Dec;98(12):4834-44. doi: 10.1210/jc.2013-2975. Epub 2013 Oct 9.

PMID:
24108314
17.

Is there an association between elevated or low serum levels of phosphorus, parathyroid hormone, and calcium and mortality in patients with end stage renal disease? A meta-analysis.

Natoli JL, Boer R, Nathanson BH, Miller RM, Chiroli S, Goodman WG, Belozeroff V.

BMC Nephrol. 2013 Apr 17;14:88. doi: 10.1186/1471-2369-14-88. Review.

18.

Calcium-mediated parathyroid hormone suppression to assess progression of secondary hyperparathyroidism during treatment among incident dialysis patients.

Rodriguez M, Ureña-Torres P, Pétavy F, Cooper K, Farouk M, Goodman WG.

J Clin Endocrinol Metab. 2013 Feb;98(2):618-25. doi: 10.1210/jc.2012-3246. Epub 2013 Jan 30.

PMID:
23365129
19.

Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis.

EVOLVE Trial Investigators, Chertow GM, Block GA, Correa-Rotter R, Drüeke TB, Floege J, Goodman WG, Herzog CA, Kubo Y, London GM, Mahaffey KW, Mix TC, Moe SM, Trotman ML, Wheeler DC, Parfrey PS.

N Engl J Med. 2012 Dec 27;367(26):2482-94. doi: 10.1056/NEJMoa1205624. Epub 2012 Nov 3.

20.

Protocol adherence and the progression of cardiovascular calcification in the ADVANCE study.

Ureña-Torres PA, Floege J, Hawley CM, Pedagogos E, Goodman WG, Pétavy F, Reiner M, Raggi P.

Nephrol Dial Transplant. 2013 Jan;28(1):146-52. doi: 10.1093/ndt/gfs356. Epub 2012 Sep 30.

PMID:
23028103
21.

Baseline characteristics of subjects enrolled in the Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) trial.

Chertow GM, Correa-Rotter R, Block GA, Drueke TB, Floege J, Goodman WG, Herzog CA, Kubo Y, London GM, Mahaffey KW, Mix TC, Moe SM, Wheeler DC, Parfrey PS.

Nephrol Dial Transplant. 2012 Jul;27(7):2872-9. doi: 10.1093/ndt/gfr777. Epub 2012 Apr 23.

PMID:
22529163
22.

Self-reported symptoms in patients on hemodialysis with moderate to severe secondary hyperparathyroidism receiving combined therapy with cinacalcet and low-dose vitamin D sterols.

Chertow GM, Lu ZJ, Xu X, Knight TG, Goodman WG, Bushinsky DA, Block GA.

Hemodial Int. 2012 Apr;16(2):188-97. doi: 10.1111/j.1542-4758.2011.00642.x.

PMID:
22118402
23.

The association of vitamin D use with hypercalcemia and hyperphosphatemia in hemodialysis patients: a case-crossover study.

Kilpatrick RD, Danese MD, Belozeroff V, Smirnakis K, Goodman WG, Rothman KJ.

Pharmacoepidemiol Drug Saf. 2011 Sep;20(9):914-21. doi: 10.1002/pds.2183. Epub 2011 Jul 7.

PMID:
21735509
24.

Control of larval-pupal-adult molt in the moth Sesamia nonagrioides by juvenile hormone and ecdysteroids.

Pérez-Hedo M, Goodman WG, Schafellner C, Martini A, Sehnal F, Eizaguirre M.

J Insect Physiol. 2011 May;57(5):602-7. doi: 10.1016/j.jinsphys.2011.01.017. Epub 2011 Feb 17.

PMID:
21315078
25.

The ADVANCE study: a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis.

Raggi P, Chertow GM, Torres PU, Csiky B, Naso A, Nossuli K, Moustafa M, Goodman WG, Lopez N, Downey G, Dehmel B, Floege J; ADVANCE Study Group.

Nephrol Dial Transplant. 2011 Apr;26(4):1327-39. doi: 10.1093/ndt/gfq725. Epub 2010 Dec 8.

PMID:
21148030
26.

Microarray analysis of juvenile hormone response in Drosophila melanogaster S2 cells.

Willis DK, Wang J, Lindholm JR, Orth A, Goodman WG.

J Insect Sci. 2010;10:66. doi: 10.1673/031.010.6601.

27.

Smile and laughter induction and intraoperative predictors of response to deep brain stimulation for obsessive-compulsive disorder.

Haq IU, Foote KD, Goodman WG, Wu SS, Sudhyadhom A, Ricciuti N, Siddiqui MS, Bowers D, Jacobson CE, Ward H, Okun MS.

Neuroimage. 2011 Jan;54 Suppl 1:S247-55. doi: 10.1016/j.neuroimage.2010.03.009. Epub 2010 Mar 10.

28.

Study design and subject baseline characteristics in the ADVANCE Study: effects of cinacalcet on vascular calcification in haemodialysis patients.

Floege J, Raggi P, Block GA, Torres PU, Csiky B, Naso A, Nossuli K, Moustafa M, Goodman WG, Lopez N, Downey G, Dehmel B, Chertow GM; ADVANCE Study group.

Nephrol Dial Transplant. 2010 Jun;25(6):1916-23. doi: 10.1093/ndt/gfp762. Epub 2010 Jan 27.

PMID:
20110249
29.

When is Vitamin D Contraindicated in Dialysis Patients?

Goodman WG.

Semin Dial. 2009 May-Jun;22(3):245-7. doi: 10.1111/j.1525-139X.2009.00565.x. Review. No abstract available.

PMID:
19573000
30.

Juvenile hormone regulation of Drosophila Epac--a guanine nucleotide exchange factor.

Wang J, Lindholm JR, Willis DK, Orth A, Goodman WG.

Mol Cell Endocrinol. 2009 Jun 16;305(1-2):30-7. doi: 10.1016/j.mce.2009.02.002. Epub 2009 Feb 21.

PMID:
19433259
31.

Cinacalcet lowers serum alkaline phosphatase in maintenance hemodialysis patients.

Belozeroff V, Goodman WG, Ren L, Kalantar-Zadeh K.

Clin J Am Soc Nephrol. 2009 Mar;4(3):673-9. doi: 10.2215/CJN.03790808. Epub 2009 Mar 4.

32.

Cinacalcet HCl and concurrent low-dose vitamin D improves treatment of secondary hyperparathyroidism in dialysis patients compared with vitamin D alone: the ACHIEVE study results.

Fishbane S, Shapiro WB, Corry DB, Vicks SL, Roppolo M, Rappaport K, Ling X, Goodman WG, Turner S, Charytan C.

Clin J Am Soc Nephrol. 2008 Nov;3(6):1718-25. doi: 10.2215/CJN.01040308.

33.

An assessment of cinacalcet HCl effects on bone histology in dialysis patients with secondary hyperparathyroidism.

Malluche HH, Monier-Faugere MC, Wang G, Frazã O JM, Charytan C, Coburn JW, Coyne DW, Kaplan MR, Baker N, McCary LC, Turner SA, Goodman WG.

Clin Nephrol. 2008 Apr;69(4):269-78.

PMID:
18397701
34.

Evaluation of Cinacalcet Therapy to Lower Cardiovascular Events (EVOLVE): rationale and design overview.

Chertow GM, Pupim LB, Block GA, Correa-Rotter R, Drueke TB, Floege J, Goodman WG, London GM, Mahaffey KW, Moe SM, Wheeler DC, Albizem M, Olson K, Klassen P, Parfrey P.

Clin J Am Soc Nephrol. 2007 Sep;2(5):898-905. Epub 2007 Aug 16.

35.

Effects of stress on the hemolymph juvenile hormone binding protein titers of Manduca sexta.

Tauchman SJ, Lorch JM, Orth AP, Goodman WG.

Insect Biochem Mol Biol. 2007 Aug;37(8):847-54. Epub 2007 Jun 2.

PMID:
17628283
36.

Development and progression of secondary hyperparathyroidism in chronic kidney disease: lessons from molecular genetics.

Goodman WG, Quarles LD.

Kidney Int. 2008 Aug;74(3):276-88. Epub 2007 Jun 13. Review.

38.

PTH(1-84)/PTH(7-84): a balance of power.

Friedman PA, Goodman WG.

Am J Physiol Renal Physiol. 2006 May;290(5):F975-84. Review.

39.

Renal osteodystrophy for nonnephrologists.

Goodman WG.

J Bone Miner Metab. 2006;24(2):161-3. Review. No abstract available.

PMID:
16502125
40.

First- and second-generation immunometric PTH assays during treatment of hyperparathyroidism with cinacalcet HCl.

Martin KJ, Jüppner H, Sherrard DJ, Goodman WG, Kaplan MR, Nassar G, Campbell P, Curzi M, Charytan C, McCary LC, Guo MD, Turner SA, Bushinsky DA.

Kidney Int. 2005 Sep;68(3):1236-43.

41.

Specific measurement of PTH (1-84) in various forms of renal osteodystrophy (ROD) as assessed by bone histomorphometry.

Lehmann G, Stein G, Hüller M, Schemer R, Ramakrishnan K, Goodman WG.

Kidney Int. 2005 Sep;68(3):1206-14.

42.

The evolution of assays for parathyroid hormone.

Goodman WG.

Semin Dial. 2005 Jul-Aug;18(4):296-301. Review.

PMID:
16076352
43.

Long-term treatment of secondary hyperparathyroidism with the calcimimetic cinacalcet HCl.

Moe SM, Cunningham J, Bommer J, Adler S, Rosansky SJ, Urena-Torres P, Albizem MB, Guo MD, Zani VJ, Goodman WG, Sprague SM.

Nephrol Dial Transplant. 2005 Oct;20(10):2186-93. Epub 2005 Jul 19.

PMID:
16030053
44.

Sevelamer controls parathyroid hormone-induced bone disease as efficiently as calcium carbonate without increasing serum calcium levels during therapy with active vitamin D sterols.

Salusky IB, Goodman WG, Sahney S, Gales B, Perilloux A, Wang HJ, Elashoff RM, Jüppner H.

J Am Soc Nephrol. 2005 Aug;16(8):2501-8. Epub 2005 Jun 8.

45.

Calcimimetics: a remedy for all problems of excess parathyroid hormone activity in chronic kidney disease?

Goodman WG.

Curr Opin Nephrol Hypertens. 2005 Jul;14(4):355-60. Review.

PMID:
15931004
46.

Calcium and phosphorus metabolism in patients who have chronic kidney disease.

Goodman WG.

Med Clin North Am. 2005 May;89(3):631-47. Review.

PMID:
15755471
47.

Achieving NKF-K/DOQI bone metabolism and disease treatment goals with cinacalcet HCl.

Moe SM, Chertow GM, Coburn JW, Quarles LD, Goodman WG, Block GA, Drüeke TB, Cunningham J, Sherrard DJ, McCary LC, Olson KA, Turner SA, Martin KJ.

Kidney Int. 2005 Feb;67(2):760-71.

48.

Calcimimetic agents for the treatment of secondary hyperparathyroidism.

Goodman WG.

Semin Nephrol. 2004 Sep;24(5):460-3. Review.

PMID:
15490411
49.

The flavors of vitamin D: tasting the molecular mechanisms.

Goodman WG.

Kidney Int. 2004 Sep;66(3):1286-7. Review. No abstract available.

50.

Supplemental Content

Loading ...
Support Center